v3.25.4
Segment Information (Details)
$ in Thousands
 12 Months Ended
Dec. 31, 2025
USD ($)
segment
Dec. 31, 2024
USD ($)
Dec. 31, 2023
USD ($)
Segment Information      
Number of reportable segment | segment 1    
Collaboration revenue $ 40,374 $ 80,001 $ 250,008
General and administrative 37,544 35,920 35,822
Interest income 10,618 18,328 11,721
Other income 1,649 622 3
Income tax provision 144 665 1,408
Net (loss) income (119,721) (65,002) 132,330
Single reportable segment      
Segment Information      
Collaboration revenue 40,374 80,001 250,008
Internal research and development 42,106 38,422 27,860
Facilities and other research and development 28,217 30,865 18,304
General and administrative 37,544 35,920 35,822
Interest income 10,618 18,328 11,721
Other income 1,649 622 3
Income tax provision 144 665 1,408
Net (loss) income (119,721) (65,002) 132,330
Single reportable segment | Anti-tau antibody program (VY7523)      
Segment Information      
External research and development 20,069 15,647 16,923
Single reportable segment | SOD1 silencing gene therapy program (VY9323)      
Segment Information      
External research and development 2,267 15,818 6,251
Single reportable segment | Tau silencing gene therapy program (VY1706)      
Segment Information      
External research and development 19,188 7,455 696
Single reportable segment | Partnered programs      
Segment Information      
External research and development 5,495 4,985 7,650
Single reportable segment | Other programs and platforms      
Segment Information      
External research and development $ 17,332 $ 14,176 $ 14,488